164 related articles for article (PubMed ID: 24258396)
1. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies].
Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S
Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396
[TBL] [Abstract][Full Text] [Related]
2. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
3. Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC).
de Martino M; Klatte T; Seemann C; Waldert M; Haitel A; Schatzl G; Remzi M; Weibl P
BJU Int; 2013 Jun; 111(8):E348-53. PubMed ID: 23495750
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy.
Bedke J; Chun FK; Merseburger A; Scharpf M; Kasprzyk K; Schilling D; Sievert KD; Stenzl A; Kruck S
BJU Int; 2012 Dec; 110(11 Pt B):E771-7. PubMed ID: 23134582
[TBL] [Abstract][Full Text] [Related]
5. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study.
Tanaka N; Kikuchi E; Shirotake S; Kanao K; Matsumoto K; Kobayashi H; Miyazaki Y; Ide H; Obata J; Hoshino K; Hayakawa N; Ito Y; Kosaka T; Kodaira K; Oyama M; Miyajima A; Momma T; Nakagawa K; Ueno M; Oya M
Eur Urol; 2014 Jan; 65(1):227-34. PubMed ID: 23219372
[TBL] [Abstract][Full Text] [Related]
8. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma.
Komai Y; Saito K; Sakai K; Morimoto S
BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357
[TBL] [Abstract][Full Text] [Related]
9. Serum level of immunosuppressive acidic protein in patients with urological malignancies.
Pu YS; Tsai TC; Chiu TY; Hsieh TS; Chen J; Chen SC; Lin MC; Hsu TC
J Formos Med Assoc; 1991 May; 90(5):498-503. PubMed ID: 1680990
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
11. [Update uro-oncology: scientific meetings 2011].
Hegele A; Skrobek L; Schrader AJ
Aktuelle Urol; 2012 Jan; 43(1):13-27. PubMed ID: 22344822
[TBL] [Abstract][Full Text] [Related]
12. High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer.
Omae K; Kondo T; Tanabe K
Urol Oncol; 2015 Feb; 33(2):67.e9-13. PubMed ID: 25130069
[TBL] [Abstract][Full Text] [Related]
13. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Novara G
Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
[No Abstract] [Full Text] [Related]
14. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder.
Hilmy M; Bartlett JM; Underwood MA; McMillan DC
Br J Cancer; 2005 Feb; 92(4):625-7. PubMed ID: 15726119
[TBL] [Abstract][Full Text] [Related]
16. Biomarker classification, validation, and what to look for in 2017 and beyond.
Davis JW
BJU Int; 2017 May; 119(5):812-814. PubMed ID: 28117555
[No Abstract] [Full Text] [Related]
17. The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma.
Teishima J; Kobatake K; Kitano H; Nagamatsu H; Sadahide K; Hieda K; Shinmei S; Shoji K; Inoue S; Hayashi T; Inoue Y; Ohara S; Mita K; Matsubara A
BJU Int; 2016 Jun; 117(6B):E67-74. PubMed ID: 26305535
[TBL] [Abstract][Full Text] [Related]
18. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M
Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922
[TBL] [Abstract][Full Text] [Related]
20. Palliative care in urology.
Wu JN; Meyers FJ; Evans CP
Surg Clin North Am; 2011 Apr; 91(2):429-44, x. PubMed ID: 21419262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
